Fig. 3
From: Mepolizumab-Induced Posterior Reversible Encephalopathy Syndrome (PRES), a new patient report
MRI sequences related to patient’s PRES. Top row Diffusion, Middle and Bottom Row FLAIR (A) Initial Presentation (B) 1-month after stopping Mepolizumab (C) 6-months after stopping Mepolizumab. Underlying white matter edema. There is also an unusual pattern of associated susceptibility artifact, which might imply a process that is hemorrhagic. In all sequences assessed, this patient’s scan is notably improved